MILESTONE SCIENTIFIC INC (MLSS) Stock Fundamental Analysis
USA - NYSEARCA:MLSS - US59935P2092 - Common Stock
0.4581 USD
+0 (+0.64%)
MLSS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. MLSS may be in some trouble as it scores bad on both profitability and health. MLSS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
MLSS had negative earnings in the past year.
MLSS had a negative operating cash flow in the past year.
MLSS had negative earnings in each of the past 5 years.
MLSS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
MLSS has a Return On Assets of -86.63%. This is in the lower half of the industry: MLSS underperforms 75.13% of its industry peers.
With a Return On Equity value of -208.80%, MLSS is not doing good in the industry: 73.55% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -86.63% | ||
| ROE | -208.8% | ||
| ROIC | N/A |
ROA(3y)-57.54%
ROA(5y)-48.91%
ROE(3y)-84.14%
ROE(5y)-67.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 72.80%, MLSS belongs to the top of the industry, outperforming 83.07% of the companies in the same industry.
In the last couple of years the Gross Margin of MLSS has grown nicely.
The Profit Margin and Operating Margin are not available for MLSS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.77%
GM growth 5Y1.76%
2. Health
2.1 Basic Checks
MLSS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MLSS has been increased compared to 1 year ago.
Compared to 5 years ago, MLSS has more shares outstanding
The debt/assets ratio for MLSS is higher compared to a year ago.
2.2 Solvency
MLSS has an Altman-Z score of -19.48. This is a bad value and indicates that MLSS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MLSS (-19.48) is worse than 90.48% of its industry peers.
MLSS has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.25, MLSS is in line with its industry, outperforming 54.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -19.48 |
ROIC/WACCN/A
WACC8.64%
2.3 Liquidity
A Current Ratio of 2.03 indicates that MLSS has no problem at all paying its short term obligations.
MLSS has a Current ratio of 2.03. This is in the lower half of the industry: MLSS underperforms 62.43% of its industry peers.
A Quick Ratio of 0.69 indicates that MLSS may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.69, MLSS is doing worse than 87.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.03 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
MLSS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -40.98%.
The Revenue has been growing slightly by 7.83% in the past year.
Measured over the past years, MLSS shows a small growth in Revenue. The Revenue has been growing by 0.61% on average per year.
EPS 1Y (TTM)-40.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)7.83%
Revenue growth 3Y-5.73%
Revenue growth 5Y0.61%
Sales Q2Q%25.31%
3.2 Future
The Earnings Per Share is expected to grow by 19.72% on average over the next years. This is quite good.
Based on estimates for the next years, MLSS will show a quite strong growth in Revenue. The Revenue will grow by 10.29% on average per year.
EPS Next Y20.67%
EPS Next 2Y19.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year6.02%
Revenue Next 2Y10.29%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MLSS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MLSS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MLSS's earnings are expected to grow with 19.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.72%
EPS Next 3YN/A
5. Dividend
5.1 Amount
MLSS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSEARCA:MLSS (10/28/2025, 8:09:10 PM)
0.4581
+0 (+0.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners5.95%
Inst Owner Change2.57%
Ins Owners6.14%
Ins Owner Change-1.45%
Market Cap35.99M
Revenue(TTM)9.08M
Net Income(TTM)-6974400
Analysts82.5
Price Target1.66 (262.37%)
Short Float %0.25%
Short Ratio1.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-63.4%
Min EPS beat(2)-96.08%
Max EPS beat(2)-30.72%
EPS beat(4)0
Avg EPS beat(4)-104.25%
Min EPS beat(4)-194.12%
Max EPS beat(4)-30.72%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-11.25%
Min Revenue beat(2)-12.41%
Max Revenue beat(2)-10.09%
Revenue beat(4)0
Avg Revenue beat(4)-13.44%
Min Revenue beat(4)-25.64%
Max Revenue beat(4)-5.64%
Revenue beat(8)0
Avg Revenue beat(8)-18.46%
Revenue beat(12)3
Avg Revenue beat(12)-10.19%
Revenue beat(16)5
Avg Revenue beat(16)-9.84%
PT rev (1m)0%
PT rev (3m)-23.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-50%
EPS NY rev (1m)0%
EPS NY rev (3m)-55.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.05%
Revenue NY rev (1m)-1.01%
Revenue NY rev (3m)-10.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.96 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 10.77 | ||
| P/tB | 11.15 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.09
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.12
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -86.63% | ||
| ROE | -208.8% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.8% | ||
| FCFM | N/A |
ROA(3y)-57.54%
ROA(5y)-48.91%
ROE(3y)-84.14%
ROE(5y)-67.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.77%
GM growth 5Y1.76%
F-Score3
Asset Turnover1.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.41% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.03 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | -19.48 |
F-Score3
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)9.14%
Cap/Depr(5y)15.64%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y20.67%
EPS Next 2Y19.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.83%
Revenue growth 3Y-5.73%
Revenue growth 5Y0.61%
Sales Q2Q%25.31%
Revenue Next Year6.02%
Revenue Next 2Y10.29%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.04%
OCF growth 3YN/A
OCF growth 5YN/A
MILESTONE SCIENTIFIC INC / MLSS FAQ
Can you provide the ChartMill fundamental rating for MILESTONE SCIENTIFIC INC?
ChartMill assigns a fundamental rating of 2 / 10 to MLSS.
What is the valuation status for MLSS stock?
ChartMill assigns a valuation rating of 0 / 10 to MILESTONE SCIENTIFIC INC (MLSS). This can be considered as Overvalued.
What is the profitability of MLSS stock?
MILESTONE SCIENTIFIC INC (MLSS) has a profitability rating of 1 / 10.